{"ticker": {"uuid": "85c57ddc-8a2e-4d4f-b454-08607a4fef0f", "symbol": "ATAI", "name": "ATAI Life Sciences BV", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZFNsdEt4c19Ma0pOejJmZmRtanZfdlc2bWNCNUp4OHMxckd3OG5HcWpMdU8zQk50TkgtMy1VTWtQTkxOTWFRVmpaaWIwYm5ITVlQMVdBWUtZZHJWeFg0T1QyMmVlWm5VRjltWnU2ZllRVl8tZ1hpd190WUlic0liWTJlUVM4RjVTQnlFbzRYVkF2aFNlSFZaOS04bkhqMVVCS2NwMkloVmtQSnl0c3hsS0ZUdjlXOGptNVJzcy04cHVNOXRE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:18:18+00:00", "published_display": "17 Jul 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOYnhyZFFiSnVMNDh0UjB4M2g3d3pTMDFxc0dPQzdpcXl1eGpIbW5ZREZ3dlhtVDJEeW1yU1g2WkZxcUtqcXAtUmVrcmhxU0Q5aE1wVGxOMkVOOWJtNDl3RjY2NVpuSWdfdVQ3MExHbmU5b21lZk9MUW1faDk4T0NmYW0tVnV1Y3BndWVpWkFoTFpRRnJoTXM4?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-17T11:50:39+00:00", "published_display": "17 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ATAI Life Sciences NV (ATAI) Institutional Confidence", "summary": "ATAI Life Sciences NV (ATAI) has an institutional shareholding score of 3.00, placing it 192nd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 83.09% quarter-over-quarter, reaching 19.93%. Catherine Wood", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T06:10:52", "published_display": "24 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "ATAI Life Sciences NV (ATAI) currently holds a financial score of 6.24, ranking 275 out of 389 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 38.65% year-over-y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T10:40:27", "published_display": "23 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ATAI Life Sciences NV (ATAI), noting its current valuation score of 6.61, ranking 314th in its industry. It highlights the company's current P/E ratio is -1.43, and mentions that relevant data for P/B, P/S, and P/CF ratios have not y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:15", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ATAI Life Sciences NV (ATAI), showing its current price momentum score as 7.15 within the Biotechnology & Medical Research industry. It identifies a trading range with resistance at $4.82 and support at $3.49, suggesting suitability f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/technical", "source_name": "TradingKey", "published_at": "2026-06-19T04:10:15", "published_display": "19 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ATAI Life Sciences NV (ATAI), showing a current earnings forecast score of 8.43. Analysts have a consensus price target of $12.00, with a strong \"Buy\" recommendation based on 14 analysts. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:14", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ATAI Life Sciences NV's (ATAI) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page primarily serves as a financial data portal fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:03", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for ATAI Life Sciences NV (ATAI) indicates that the company has not yet disclosed relevant data regarding its revenue breakdown by business segment or by region. The page displays ATAI's current stock price, market cap, and links to other financial analysis sections,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ATAI Life Sciences NV's shareholder structure, including major shareholders and institutional holdings. It lists the proportion of shares held by various investor types like family offices, investment advisors, and hedge funds, alongs", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TradingKey", "summary": "The page displays real-time stock information for ATAI Life Sciences NV (ATAI), showing its current price, daily change, and after-hours trading data. It includes a market capitalization and various sections like Overview, Financials, Discussions, and Analysis. The platform also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/comments", "source_name": "TradingKey", "published_at": "2026-05-11T21:39:07", "published_display": "11 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "InvestingPro\u2019s fair value model accurately predicted Atai\u2019s 38% decline By Investing.com", "summary": "InvestingPro's Fair Value analysis accurately predicted a 38% decline in Atai Life Sciences (NASDAQ:ATAI) shares. In October 2025, when the stock traded at $6.45, the model identified significant overvaluation and projected a 35% downside. This prediction was validated as shares ", "url": "https://www.investing.com/news/investment-ideas/investingpros-fair-value-model-accurately-predicted-atais-38-decline-93CH-4662604", "source_name": "Investing.com", "published_at": "2026-05-06T07:02:00", "published_display": "06 May 2026 07:02", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "atai Life Sciences, Beckley Psytech get FDA breakthrough therapy status for BPL-003", "summary": "The article reports that atai Life Sciences and Beckley Psytech have received FDA breakthrough therapy designation for their drug candidate BPL-003. This status is granted to therapies that show substantial improvement over available treatments for serious conditions. The article", "url": "http://www.msn.com/en-us/health/other/atai-life-sciences-beckley-psytech-get-fda-breakthrough-therapy-status-for-bpl-003/ar-AA1OCu6M?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-04-11T04:40:59", "published_display": "11 Apr 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences Soars 14.75%, Hits Intraday High of $3.91", "summary": "ATAI Life Sciences NV saw a significant surge in stock price, rising 14.75% to an intraday high of $3.91, significantly outperforming the S&P 500 on the same day and over the past week. Despite impressive annual growth of 157.62%, the company faces year-to-date declines and finan", "url": "https://www.marketsmojo.com/news/stocks-in-action/atai-life-sciences-soars-1475-hits-intraday-high-of-391-3883321", "source_name": "Markets Mojo", "published_at": "2026-03-30T22:40:07", "published_display": "30 Mar 2026 22:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AtaiBeckley Inc. Trade Ideas \u2014 TRADEGATE:B72", "summary": "This article compiles various trade ideas and technical analyses for AtaiBeckley Inc. (TRADEGATE:B72), also referred to as ATAI Life Sciences. Traders analyze its stock performance, support and resistance levels, market capitalization, and potential for rebounds, particularly wit", "url": "https://www.tradingview.com/symbols/TRADEGATE-B72/ideas/", "source_name": "TradingView", "published_at": "2026-03-27T09:39:01", "published_display": "27 Mar 2026 09:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates atai Life Sciences stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for atai Life Sciences (NASDAQ: ATAI) following a virtual investor day. The company unveiled its ReConnection Phase 3 pivotal program for BPL-003, with trials expected to start in Q2 2026 and topline data in ea", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-atai-life-sciences-stock-rating-at-buy-93CH-4551953", "source_name": "Investing.com", "published_at": "2026-03-10T08:16:00", "published_display": "10 Mar 2026 08:16", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates atai Life Sciences stock rating on pipeline progress", "summary": "Jefferies has reiterated a Buy rating and a $10.00 price target for atai Life Sciences (NASDAQ: ATAI), citing significant pipeline advancements. Key developments include BPL-003, an intranasal 5-MeO-DMT treatment, entering two Phase III trials for treatment-resistant depression i", "url": "https://www.investing.com/news/analyst-ratings/jefferies-reiterates-atai-life-sciences-stock-rating-on-pipeline-progress-93CH-4547892", "source_name": "Investing.com", "published_at": "2026-03-06T21:53:36", "published_display": "06 Mar 2026 21:53", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences Forms Death Cross, Signaling Potential Bearish Trend", "summary": "ATAI Life Sciences NV has recently formed a \"Death Cross,\" a technical indicator suggesting a potential bearish trend. While the stock has seen a significant annual gain of 123.03%, it has declined by 1.34% today and 5.15% over the past week, resulting in a year-to-date performan", "url": "https://www.marketsmojo.com/news/across-the-web/stock-market-holiday-are-bse-nse-open-or-closed-on-wednesday-for-holi-3867092", "source_name": "Markets Mojo", "published_at": "2026-03-03T12:52:17", "published_display": "03 Mar 2026 12:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley To Host Virtual Investor Day on March 6, 2026", "summary": "AtaiBeckley Inc. (NASDAQ: ATAI) announced it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and Q&A sessions with executive leadership and external key opinion leaders, focusing on the company's mis", "url": "https://investingnews.com/ataibeckley-to-host-virtual-investor-day-on-march-6-2026/", "source_name": "Investing News Network", "published_at": "2026-02-20T12:52:18", "published_display": "20 Feb 2026 12:52", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley Appoints Michael Faerm as Chief Financial Officer", "summary": "AtaiBeckley Inc. has appointed Michael Faerm as its new Chief Financial Officer, effective March 9, 2026. Faerm brings over 25 years of experience in life sciences finance, equity research, and investment banking, and will oversee the company's financial strategy and capital mark", "url": "https://investingnews.com/ataibeckley-appoints-michael-faerm-as-chief-financial-officer/", "source_name": "Investing News Network", "published_at": "2026-02-19T14:27:44", "published_display": "19 Feb 2026 14:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Stock Forecast: Analyzing atai Life Sciences Market Outlook", "summary": "This article provides a stock forecast for atai Life Sciences (ATAI), highlighting a highly optimistic outlook from financial analysts with a \"Strong Buy\" consensus and significant potential upside. The forecast is driven by progress in their clinical pipeline, particularly BPL-0", "url": "https://www.bitget.com/wiki/atai-stock-forecast", "source_name": "Bitget", "published_at": "2026-02-06T09:39:44", "published_display": "06 Feb 2026 09:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOaGJRQkcxNnBHeWJqeHZURUw0aGQ5QWNrVF9QMVFjQm1LRm0xNFk3LU4yeDVpTE1BZnF5dUVoU1dFLXhTNG0xUlVaaWMySXVIN3hJMXNENXA2QW5EaVRZUDlMRWgwMkplV1B5SGo4Qk0yMVQ1N0JhaG1TOTlZMHpwb0pJdE5kUQ?oc=5", "source_name": "Market source", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences (ATAI): Assessing an 8.8x Price-to-Book Valuation After a Volatile Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOVC11SzFzUkliN3l1dld0VTZ2d29EdnRWSTZFZkx2VkVReW5oLVkzRVZ1UTFwLTFjSVlTYVA5dWFsVzdtdzlSNkJFaVR5NHJQOUxlZkx4a1JIVVNja282OFhmcEFyQ3VYd0hqX2dFVG1tOU9NeGxMNjdpMlZibGJjLWtWNWdNQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPQVVhZ3hTVjg5UnJoWUVIcDNhX1loZmRmSHpfdWM4NGVIWTdlT0FIRlM3QUFQR1RlZ0QzYlhaWFQtTjM0a0FiZlozZ045dFlBU3pDaXZ0NERnSklvZk5MTkRwMjliemhQVkgxSTNmbVd2RWVmZGZvMGtiYnhjaGc2enZHQTMzYW1KUGNKb3JzNjZ0a3VnSmtsWjdKUUNqWm44ZkVSaENGZ2o3WFlRQ1pEQWU5akI5TFhKRS1kZUFWd1BHVkpNYTZyZHR2eUJQNWp5am9PWFJYakRFZlZOVnNDeA?oc=5", "source_name": "Investing News Network", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences Second Quarter 2025 Earnings: US$0.14 loss per share (vs US$0.36 loss in 2Q 2024)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9GYkpaY3Rxc0xPbDgtYzRxejc0dmlUc2RESnpUMkVwQ3RQQl9YSDQ2VFJOZHRWU3NKU1ZGUEd0Q1NjMEFjVlB1UDZYVlBjRk1Dc2t2MUllV0tXd28zZE5lYzh1MlNja1hFaTBpbHFzU3VId19HWjc4?oc=5", "source_name": "Market source", "published_at": "2025-03-01T08:00:00+00:00", "published_display": "01 Mar 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZFNsdEt4c19Ma0pOejJmZmRtanZfdlc2bWNCNUp4OHMxckd3OG5HcWpMdU8zQk50TkgtMy1VTWtQTkxOTWFRVmpaaWIwYm5ITVlQMVdBWUtZZHJWeFg0T1QyMmVlWm5VRjltWnU2ZllRVl8tZ1hpd190WUlic0liWTJlUVM4RjVTQnlFbzRYVkF2aFNlSFZaOS04bkhqMVVCS2NwMkloVmtQSnl0c3hsS0ZUdjlXOGptNVJzcy04cHVNOXRE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T21:18:18+00:00", "published_display": "17 Jul 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOYnhyZFFiSnVMNDh0UjB4M2g3d3pTMDFxc0dPQzdpcXl1eGpIbW5ZREZ3dlhtVDJEeW1yU1g2WkZxcUtqcXAtUmVrcmhxU0Q5aE1wVGxOMkVOOWJtNDl3RjY2NVpuSWdfdVQ3MExHbmU5b21lZk9MUW1faDk4T0NmYW0tVnV1Y3BndWVpWkFoTFpRRnJoTXM4?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-17T11:50:39+00:00", "published_display": "17 Jul 2026 11:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Institutional Confidence", "summary": "ATAI Life Sciences NV (ATAI) has an institutional shareholding score of 3.00, placing it 192nd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 83.09% quarter-over-quarter, reaching 19.93%. Catherine Wood", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T06:10:52", "published_display": "24 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "ATAI Life Sciences NV (ATAI) currently holds a financial score of 6.24, ranking 275 out of 389 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 38.65% year-over-y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T10:40:27", "published_display": "23 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ATAI Life Sciences NV (ATAI), noting its current valuation score of 6.61, ranking 314th in its industry. It highlights the company's current P/E ratio is -1.43, and mentions that relevant data for P/B, P/S, and P/CF ratios have not y", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:15", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ATAI Life Sciences NV (ATAI), showing its current price momentum score as 7.15 within the Biotechnology & Medical Research industry. It identifies a trading range with resistance at $4.82 and support at $3.49, suggesting suitability f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/technical", "source_name": "TradingKey", "published_at": "2026-06-19T04:10:15", "published_display": "19 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for ATAI Life Sciences NV (ATAI), showing a current earnings forecast score of 8.43. Analysts have a consensus price target of $12.00, with a strong \"Buy\" recommendation based on 14 analysts. The company's expected revenue for the next q", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:14", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ATAI Life Sciences NV's (ATAI) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page primarily serves as a financial data portal fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:03", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for ATAI Life Sciences NV (ATAI) indicates that the company has not yet disclosed relevant data regarding its revenue breakdown by business segment or by region. The page displays ATAI's current stock price, market cap, and links to other financial analysis sections,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences NV (ATAI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ATAI Life Sciences NV's shareholder structure, including major shareholders and institutional holdings. It lists the proportion of shares held by various investor types like family offices, investment advisors, and hedge funds, alongs", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "The page displays real-time stock information for ATAI Life Sciences NV (ATAI), showing its current price, daily change, and after-hours trading data. It includes a market capitalization and various sections like Overview, Financials, Discussions, and Analysis. The platform also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atai/comments", "source_name": "TradingKey", "published_at": "2026-05-11T21:39:07", "published_display": "11 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InvestingPro\u2019s fair value model accurately predicted Atai\u2019s 38% decline By Investing.com", "summary": "InvestingPro's Fair Value analysis accurately predicted a 38% decline in Atai Life Sciences (NASDAQ:ATAI) shares. In October 2025, when the stock traded at $6.45, the model identified significant overvaluation and projected a 35% downside. This prediction was validated as shares ", "url": "https://www.investing.com/news/investment-ideas/investingpros-fair-value-model-accurately-predicted-atais-38-decline-93CH-4662604", "source_name": "Investing.com", "published_at": "2026-05-06T07:02:00", "published_display": "06 May 2026 07:02", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "atai Life Sciences, Beckley Psytech get FDA breakthrough therapy status for BPL-003", "summary": "The article reports that atai Life Sciences and Beckley Psytech have received FDA breakthrough therapy designation for their drug candidate BPL-003. This status is granted to therapies that show substantial improvement over available treatments for serious conditions. The article", "url": "http://www.msn.com/en-us/health/other/atai-life-sciences-beckley-psytech-get-fda-breakthrough-therapy-status-for-bpl-003/ar-AA1OCu6M?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-04-11T04:40:59", "published_display": "11 Apr 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences Soars 14.75%, Hits Intraday High of $3.91", "summary": "ATAI Life Sciences NV saw a significant surge in stock price, rising 14.75% to an intraday high of $3.91, significantly outperforming the S&P 500 on the same day and over the past week. Despite impressive annual growth of 157.62%, the company faces year-to-date declines and finan", "url": "https://www.marketsmojo.com/news/stocks-in-action/atai-life-sciences-soars-1475-hits-intraday-high-of-391-3883321", "source_name": "Markets Mojo", "published_at": "2026-03-30T22:40:07", "published_display": "30 Mar 2026 22:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley Inc. Trade Ideas \u2014 TRADEGATE:B72", "summary": "This article compiles various trade ideas and technical analyses for AtaiBeckley Inc. (TRADEGATE:B72), also referred to as ATAI Life Sciences. Traders analyze its stock performance, support and resistance levels, market capitalization, and potential for rebounds, particularly wit", "url": "https://www.tradingview.com/symbols/TRADEGATE-B72/ideas/", "source_name": "TradingView", "published_at": "2026-03-27T09:39:01", "published_display": "27 Mar 2026 09:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates atai Life Sciences stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for atai Life Sciences (NASDAQ: ATAI) following a virtual investor day. The company unveiled its ReConnection Phase 3 pivotal program for BPL-003, with trials expected to start in Q2 2026 and topline data in ea", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-atai-life-sciences-stock-rating-at-buy-93CH-4551953", "source_name": "Investing.com", "published_at": "2026-03-10T08:16:00", "published_display": "10 Mar 2026 08:16", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates atai Life Sciences stock rating on pipeline progress", "summary": "Jefferies has reiterated a Buy rating and a $10.00 price target for atai Life Sciences (NASDAQ: ATAI), citing significant pipeline advancements. Key developments include BPL-003, an intranasal 5-MeO-DMT treatment, entering two Phase III trials for treatment-resistant depression i", "url": "https://www.investing.com/news/analyst-ratings/jefferies-reiterates-atai-life-sciences-stock-rating-on-pipeline-progress-93CH-4547892", "source_name": "Investing.com", "published_at": "2026-03-06T21:53:36", "published_display": "06 Mar 2026 21:53", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Life Sciences Forms Death Cross, Signaling Potential Bearish Trend", "summary": "ATAI Life Sciences NV has recently formed a \"Death Cross,\" a technical indicator suggesting a potential bearish trend. While the stock has seen a significant annual gain of 123.03%, it has declined by 1.34% today and 5.15% over the past week, resulting in a year-to-date performan", "url": "https://www.marketsmojo.com/news/across-the-web/stock-market-holiday-are-bse-nse-open-or-closed-on-wednesday-for-holi-3867092", "source_name": "Markets Mojo", "published_at": "2026-03-03T12:52:17", "published_display": "03 Mar 2026 12:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley To Host Virtual Investor Day on March 6, 2026", "summary": "AtaiBeckley Inc. (NASDAQ: ATAI) announced it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and Q&A sessions with executive leadership and external key opinion leaders, focusing on the company's mis", "url": "https://investingnews.com/ataibeckley-to-host-virtual-investor-day-on-march-6-2026/", "source_name": "Investing News Network", "published_at": "2026-02-20T12:52:18", "published_display": "20 Feb 2026 12:52", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AtaiBeckley Appoints Michael Faerm as Chief Financial Officer", "summary": "AtaiBeckley Inc. has appointed Michael Faerm as its new Chief Financial Officer, effective March 9, 2026. Faerm brings over 25 years of experience in life sciences finance, equity research, and investment banking, and will oversee the company's financial strategy and capital mark", "url": "https://investingnews.com/ataibeckley-appoints-michael-faerm-as-chief-financial-officer/", "source_name": "Investing News Network", "published_at": "2026-02-19T14:27:44", "published_display": "19 Feb 2026 14:27", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATAI Stock Forecast: Analyzing atai Life Sciences Market Outlook", "summary": "This article provides a stock forecast for atai Life Sciences (ATAI), highlighting a highly optimistic outlook from financial analysts with a \"Strong Buy\" consensus and significant potential upside. The forecast is driven by progress in their clinical pipeline, particularly BPL-0", "url": "https://www.bitget.com/wiki/atai-stock-forecast", "source_name": "Bitget", "published_at": "2026-02-06T09:39:44", "published_display": "06 Feb 2026 09:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOaGJRQkcxNnBHeWJqeHZURUw0aGQ5QWNrVF9QMVFjQm1LRm0xNFk3LU4yeDVpTE1BZnF5dUVoU1dFLXhTNG0xUlVaaWMySXVIN3hJMXNENXA2QW5EaVRZUDlMRWgwMkplV1B5SGo4Qk0yMVQ1N0JhaG1TOTlZMHpwb0pJdE5kUQ?oc=5", "source_name": "Market source", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences (ATAI): Assessing an 8.8x Price-to-Book Valuation After a Volatile Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOVC11SzFzUkliN3l1dld0VTZ2d29EdnRWSTZFZkx2VkVReW5oLVkzRVZ1UTFwLTFjSVlTYVA5dWFsVzdtdzlSNkJFaVR5NHJQOUxlZkx4a1JIVVNja282OFhmcEFyQ3VYd0hqX2dFVG1tOU9NeGxMNjdpMlZibGJjLWtWNWdNQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-03T08:00:00+00:00", "published_display": "03 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPQVVhZ3hTVjg5UnJoWUVIcDNhX1loZmRmSHpfdWM4NGVIWTdlT0FIRlM3QUFQR1RlZ0QzYlhaWFQtTjM0a0FiZlozZ045dFlBU3pDaXZ0NERnSklvZk5MTkRwMjliemhQVkgxSTNmbVd2RWVmZGZvMGtiYnhjaGc2enZHQTMzYW1KUGNKb3JzNjZ0a3VnSmtsWjdKUUNqWm44ZkVSaENGZ2o3WFlRQ1pEQWU5akI5TFhKRS1kZUFWd1BHVkpNYTZyZHR2eUJQNWp5am9PWFJYakRFZlZOVnNDeA?oc=5", "source_name": "Investing News Network", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences Second Quarter 2025 Earnings: US$0.14 loss per share (vs US$0.36 loss in 2Q 2024)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-17T07:00:00+00:00", "published_display": "17 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9GYkpaY3Rxc0xPbDgtYzRxejc0dmlUc2RESnpUMkVwQ3RQQl9YSDQ2VFJOZHRWU3NKU1ZGUEd0Q1NjMEFjVlB1UDZYVlBjRk1Dc2t2MUllV0tXd28zZE5lYzh1MlNja1hFaTBpbHFzU3VId19HWjc4?oc=5", "source_name": "Market source", "published_at": "2025-03-01T08:00:00+00:00", "published_display": "01 Mar 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 115, "total_relevant": 35, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 18, "score": 56, "total": 35, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 8.8, "count": 16}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 5.17, "latest_week": "2026-07-10", "one_week_move": -0.4, "four_week_move": 31.9, "twelve_week_move": 28.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.356207, "market_dynamics_buy_signal": false, "relative_strength": 4.129168, "fair_value_gap": 108.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 42.8571, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, +31.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 9}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Investing News Network", "count": 3}, {"label": "Markets Mojo", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "Stock Titan", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 26}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 16}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "26", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.4% over one week, +31.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal"}], "updated_at": "2026-07-18T03:38:54.710051+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}